Showing results (71-80 of 204) with videos related to

Sort By:
Pageof 21
Plos One|May 6, 2010
c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589John Kauh, Songqing Fan, Mingjing Xia, et al.
Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences|December 10, 2013
[Lung MRI at 3T: comparison of CT and MRI in initial evaluation of pulmonary alveolar proteinosis]Jianguang Luo, Dongyi Yang, Enhua Xiao, et al.
Pathology Oncology Research : POR|November 12, 2021
Aberrant Expression of β-Catenin Correlates with Infiltrating Immune Cells and Prognosis in NSCLCHongmei Zheng, Yue Ning, Yang Yang, et al.
Plos One|June 23, 2022
Overexpression of p-4EBP1 associates with p-eIF4E and predicts poor prognosis for non-small cell lung cancer patients with resectionYaoxiang Tang, Jiadi Luo, Yang Yang, et al.
Journal of Cancer Research and Therapeutics|July 5, 2018
Post-transcriptional regulation DPC4 gene by miR-190 in colorectal cancer cellsBin Xie, Zhenghao Deng, Yu Pan, et al.
Oncotarget|September 15, 2016
CD74 interacts with CD44 and enhances tumorigenesis and metastasis via RHOA-mediated cofilin phosphorylation in human breast cancer cellsZhiyong Liu, Shuzhou Chu, Shun Yao, et al.
Scientific Reports|April 6, 2026
RNA-based next-generation sequencing strategy for screening MDM2-amplified sarcomasCheng Lei, Hongjing Zang, Haixia Zhang, et al.
Pathology, Research and Practice|June 15, 2026
HSP10, HSP60, and HSP70 overexpression associates with PD-L1 upregulation and adverse outcomes in on-small cell lung cancerYuling Zhang, Ying Zhou, Yang Yang, et al.
Cancer|January 31, 2020
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)Hongjing Zang, Guoqing Qian, Dan Zong, et al.
Molecular Oncology|February 1, 2020
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiolHongjing Zang, Guoqing Qian, Jack Arbiser, et al.
Pageof 21